Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Sees Large Decline in Short Interest

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) was the recipient of a large decline in short interest in the month of September. As of September 15th, there was short interest totalling 12,530,000 shares, a decline of 6.4% from the August 31st total of 13,390,000 shares. Based on an average daily volume of 2,170,000 shares, the short-interest ratio is currently 5.8 days.

Citius Pharmaceuticals Price Performance

Shares of NASDAQ:CTXR opened at $0.47 on Wednesday. Citius Pharmaceuticals has a 1 year low of $0.44 and a 1 year high of $1.07. The business’s 50-day moving average is $0.65 and its 200-day moving average is $0.70. The company has a market capitalization of $84.57 million, a price-to-earnings ratio of -1.95 and a beta of 1.60.

Citius Pharmaceuticals (NASDAQ:CTXR) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.01). Analysts anticipate that Citius Pharmaceuticals will post -0.21 EPS for the current year.

Wall Street Analyst Weigh In

Separately, EF Hutton Acquisition Co. I upgraded shares of Citius Pharmaceuticals to a “strong-buy” rating in a research report on Monday, July 15th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of CTXR. Point72 DIFC Ltd bought a new stake in Citius Pharmaceuticals in the second quarter valued at $29,000. BNP Paribas Financial Markets increased its position in Citius Pharmaceuticals by 88.5% in the 1st quarter. BNP Paribas Financial Markets now owns 69,615 shares of the company’s stock valued at $62,000 after buying an additional 32,686 shares in the last quarter. Cubist Systematic Strategies LLC bought a new stake in Citius Pharmaceuticals in the 2nd quarter valued at about $69,000. Arkadios Wealth Advisors raised its stake in Citius Pharmaceuticals by 50.0% during the 2nd quarter. Arkadios Wealth Advisors now owns 150,000 shares of the company’s stock worth $88,000 after buying an additional 50,000 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Citius Pharmaceuticals in the second quarter worth approximately $118,000. 16.88% of the stock is owned by institutional investors.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.